Aehr Test Systems Triples Revenue to $33 Million, Lifts Outlook

Aehr Test Systems reported first-quarter fiscal 2027 revenue of $33 million, triple the $11 million it booked a year earlier, and raised its full-year sales guidance to $150 million. The stock jumped 26.5% the day after the report, marking the fourth straight quarter in which shares rose 15 percent or more after earnings. The result also beat analyst estimates near $27.5 million.

The Fremont, California maker of semiconductor wafer-level burn-in and test systems is riding the same wave that has lifted much of the AI supply chain. Its equipment conditions and stress-tests chips before they ship, a step that matters most when processors are expensive and volumes are large — as they now are for AI accelerators. Note that Aehr's fiscal year runs ahead of the standard reporting calendar.

What did the numbers show?

The quarter was strong on nearly every line:

• Revenue: $33 million, up 200 percent year over year and above estimates near $27.5 million.
• Adjusted EPS: 28 cents, versus 1 cent a year ago and 11 cents last quarter; consensus expected 11 cents.
• GAAP diluted EPS: a profit of 21 cents, against a loss of 7 cents a year earlier.
• Adjusted gross margin: 48.5 percent, up 11 percentage points.
• Bookings: $46.7 million, a book-to-bill ratio of 1.4.
• Effective backlog: $109.3 million, including orders received after quarter end.

On the strength of that demand, Aehr raised the midpoint of its FY2027 guidance by 7.1 percent, from $140 million to $150 million. That implies full-year growth of 200 percent. The company also expects adjusted net income of at least 20 percent of revenue, which would put the figure at $30 million or more — against less than $1 million last year.

Is the guidance credible?

By the arithmetic, yes. Aehr has recognized $33 million of revenue, leaving a $117 million gap to its $150 million target. The $109.3 million backlog nearly closes that gap on its own. Under that assumption, the company would need only $7.7 million of additional orders to hit its outlook — roughly one-sixth of the $46.7 million it booked in the first quarter alone.

Lake Street analyst Max Michaelis made the point on the earnings call, saying the guidance felt "almost conservative." CEO Gayn Erickson responded that the company is "trying to be conservative," and noted that backlog delivery timelines map closely to FY2027. Erickson also said Aehr is not supply constrained and could ship more than $150 million if it wins more orders.

Where could the next leg of growth come from?

Beyond the current backlog, Aehr says it has made "significant progress with a major supplier of AI accelerators, CPUs and network processors." That supplier has agreed to buy a FOX-XP burn-in system for installation in early calendar 2027, to be evaluated in a high-volume production environment. A larger order decision would follow in subsequent months. Aehr describes this as one of the largest potential burn-in opportunities it has ever pursued. It remains an evaluation, not a confirmed production win.

What are the risks?

Three stand out:

• AI spending volatility. Shares fell 19.2 percent on Nov. 5 during a broader sell-off in AI-related stocks, and any perceived slowdown in the AI infrastructure buildout would likely hit Aehr hard. Investors are also watching whether Democratic midterm victories could slow that buildout.
• Valuation. The stock trades at a forward price-to-sales ratio of roughly 12x, down from earlier highs but still leaving little room for missed growth expectations. Its trailing P/E sits above 1,680, a figure only a steep growth ramp can justify. The consensus price target of $118.75 across eight analysts implies about 82 percent upside from a recent $65.06.
• Customer concentration. Nearly 73 percent of last quarter's sales came from just two customers. Losing either would materially damage the outlook. Winning the AI accelerator supplier now evaluating the FOX-XP would be the obvious path to diluting that concentration.

Aehr's own order book says the raised outlook is attainable; the stock chart says the market has already priced in considerably more. Whether the FOX-XP evaluation converts into one of the largest orders in company history will likely decide which of those two signals was right.